SuperworthAlto Neuroscience market cap ANRO
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Oct 23, 2026
- $862.1M
- Highest close in our data
- $1.4B
- Sep 2026
Alto Neuroscience is worth $862.1M at the close on Oct 23, 2026, at $21.97 a share.
That is up 189% over the last year.
Its highest close in our data was $1.4B in Sep 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $862.1M | $472.8M | $1.4B | +51% |
| 2025 | $572.6M | $48.7M | $620.7M | +393% |
| 2024 | $116.2M | $103.3M | $403M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Alto Neuroscience's size, closest first, today.
| Company | Market cap |
|---|---|
| ANROAlto Neuroscience | $862.1M |
| ABUSArbutus Biopharma | $831M |
| COLLCollegium Pharmaceutical | $747.5M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| CRMDCorMedix | $611.9M |
| ZVRAZevra Therapeutics | $582.6M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| PBYIPuma Biotechnology | $568.9M |
| PCRXPacira BioSciences | $1.5B |
| ANABAnaptysbio | $1.5B |
| Peer median | $789.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Alto Neuroscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.